0001879971-23-000002.txt : 20231002 0001879971-23-000002.hdr.sgml : 20231002 20231002170026 ACCESSION NUMBER: 0001879971-23-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20231002 DATE AS OF CHANGE: 20231002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Seabaugh Ramona CENTRAL INDEX KEY: 0001879971 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36533 FILM NUMBER: 231300486 MAIL ADDRESS: STREET 1: C/O MEDAVAIL TECHNOLOGIES INC. STREET 2: 6665 MILLCREEK DR, UNIT 1 CITY: MISSISSAUGA STATE: A6 ZIP: L5N 5M4 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MedAvail Holdings, Inc. CENTRAL INDEX KEY: 0001402479 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 900772394 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4720 E COTTON GIN LOOP STREET 2: SUITE 220 CITY: PHOENIX STATE: AZ ZIP: 85040 BUSINESS PHONE: 1.877.830.0826 MAIL ADDRESS: STREET 1: 4720 E COTTON GIN LOOP STREET 2: SUITE 220 CITY: PHOENIX STATE: AZ ZIP: 85040 FORMER COMPANY: FORMER CONFORMED NAME: MYOS RENS TECHNOLOGY INC. DATE OF NAME CHANGE: 20160322 FORMER COMPANY: FORMER CONFORMED NAME: MYOS Corp DATE OF NAME CHANGE: 20120521 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Therapeutics Corp DATE OF NAME CHANGE: 20100719 4 1 primary_doc.xml PRIMARY DOCUMENT X0508 4 2023-09-01 0 0001402479 MedAvail Holdings, Inc. MDVL 0001879971 Seabaugh Ramona C/O MEDAVAIL TECHNOLOGIES INC. 4720 E. COTTON GIN LOOP, SUITE 220 PHOENIX AZ 85040 0 1 0 0 Chief Financial Officer 1 Common Stock 2023-09-01 4 M 0 680 0 A 1525 D Common Stock 2023-09-28 4 S 0 303 5.6971 D 1222 D Restricted Stock Units 2023-09-01 4 M 0 680 0 D 2031-09-20 Common Stock 680 679 D On July 31, 2023, the Issuer effected a 1-for-50 reverse stock split of the issued and outstanding shares of its common stock. Upon effectiveness of the reverse stock split, every 50 shares of common stock were automatically converted into one share of common stock. The securities reported on this Form 4 have been adjusted to reflect the reverse stock split. This amount includes 480 net shares acquired by the reporting person upon the vesting of 680 restricted stock units on September 1, 2022. 200 shares were withheld by the Issuer in payment of the reporting person's tax liability. The disposition of the restricted stock units and the acquisition of the shares of common stock that occurred upon vesting of the restricted stock units were not previously reported by the reporting person. The reporting person sold these shares pursuant to an arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 solely to cover tax withholding obligations in connection with the vesting of restricted stock units. These shares were sold in multiple transactions at prices ranging from $5.69 to $5.98, inclusive. The prices reported in this Form 4 reflect the weighted-average sale price. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. The amount reflected has been rounded to four decimal points. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. On September 20, 2021, the reporting person was granted 2,039 restricted stock units under the Issuer's 2020 Equity Incentive Plan, with one third (1/3rd) of the units scheduled to vest on each of the one (1), two (2), and three (3) year anniversaries of September 1, 2021, the vesting commencement date. This amount excludes 680 shares disposed of by the reporting person upon the vesting of restricted stock units on September 1, 2022. The disposition of the restricted stock units and the acquisition of the shares of common stock that occurred upon vesting of the restricted stock units were not previously reported by the reporting person. /s/Ramona Seabaugh 2023-10-02